Logo image of DNLI

DENALI THERAPEUTICS INC (DNLI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:DNLI - US24823R1059 - Common Stock

17.66 USD
-0.33 (-1.83%)
Last: 1/20/2026, 12:08:52 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to DNLI. DNLI was compared to 525 industry peers in the Biotechnology industry. While DNLI seems to be doing ok healthwise, there are quite some concerns on its profitability. DNLI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year DNLI has reported negative net income.
  • In the past year DNLI has reported a negative cash flow from operations.
  • In the past 5 years DNLI reported 4 times negative net income.
  • DNLI had negative operating cash flow in 4 of the past 5 years.
DNLI Yearly Net Income VS EBIT VS OCF VS FCFDNLI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

1.2 Ratios

  • The Return On Assets of DNLI (-41.07%) is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -46.63%, DNLI is in the better half of the industry, outperforming 68.00% of the companies in the same industry.
Industry RankSector Rank
ROA -41.07%
ROE -46.63%
ROIC N/A
ROA(3y)-21.89%
ROA(5y)-16.39%
ROE(3y)-26.58%
ROE(5y)-20.75%
ROIC(3y)N/A
ROIC(5y)N/A
DNLI Yearly ROA, ROE, ROICDNLI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40 -50

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for DNLI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNLI Yearly Profit, Operating, Gross MarginsDNLI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

5

2. Health

2.1 Basic Checks

  • DNLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for DNLI has been increased compared to 1 year ago.
  • Compared to 5 years ago, DNLI has more shares outstanding
  • DNLI has a worse debt/assets ratio than last year.
DNLI Yearly Shares OutstandingDNLI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
DNLI Yearly Total Debt VS Total AssetsDNLI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • DNLI has an Altman-Z score of 8.57. This indicates that DNLI is financially healthy and has little risk of bankruptcy at the moment.
  • DNLI's Altman-Z score of 8.57 is amongst the best of the industry. DNLI outperforms 80.57% of its industry peers.
  • DNLI has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.01, DNLI perfoms like the industry average, outperforming 46.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 8.57
ROIC/WACCN/A
WACC8.88%
DNLI Yearly LT Debt VS Equity VS FCFDNLI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 10.27 indicates that DNLI has no problem at all paying its short term obligations.
  • DNLI has a Current ratio of 10.27. This is amongst the best in the industry. DNLI outperforms 81.90% of its industry peers.
  • DNLI has a Quick Ratio of 10.27. This indicates that DNLI is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 10.27, DNLI belongs to the best of the industry, outperforming 81.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.27
Quick Ratio 10.27
DNLI Yearly Current Assets VS Current LiabilitesDNLI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

3

3. Growth

3.1 Past

  • The earnings per share for DNLI have decreased by -1.75% in the last year.
  • Looking at the last year, DNLI shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-1.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.46%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 11.63% on average over the next years. This is quite good.
  • DNLI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 133.17% yearly.
EPS Next Y-12.62%
EPS Next 2Y-5.62%
EPS Next 3Y-0.54%
EPS Next 5Y11.63%
Revenue Next Year-87.68%
Revenue Next 2Y124.04%
Revenue Next 3Y166.11%
Revenue Next 5Y133.17%

3.3 Evolution

DNLI Yearly Revenue VS EstimatesDNLI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
DNLI Yearly EPS VS EstimatesDNLI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DNLI. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DNLI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNLI Price Earnings VS Forward Price EarningsDNLI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNLI Per share dataDNLI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.62%
EPS Next 3Y-0.54%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for DNLI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

DENALI THERAPEUTICS INC

NASDAQ:DNLI (1/20/2026, 12:08:52 PM)

17.66

-0.33 (-1.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-25
Inst Owners91.98%
Inst Owner Change0.76%
Ins Owners4.28%
Ins Owner Change0.96%
Market Cap2.59B
Revenue(TTM)N/A
Net Income(TTM)-478.94M
Analysts88.33
Price Target33.24 (88.22%)
Short Float %11.09%
Short Ratio9.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.78%
Min EPS beat(2)-11.43%
Max EPS beat(2)1.88%
EPS beat(4)2
Avg EPS beat(4)2.05%
Min EPS beat(4)-11.43%
Max EPS beat(4)18.24%
EPS beat(8)4
Avg EPS beat(8)2.77%
EPS beat(12)6
Avg EPS beat(12)25.16%
EPS beat(16)7
Avg EPS beat(16)14.02%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)0
Avg Revenue beat(8)-98.61%
Revenue beat(12)2
Avg Revenue beat(12)97.93%
Revenue beat(16)4
Avg Revenue beat(16)68.59%
PT rev (1m)1.15%
PT rev (3m)1.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.17%
EPS NY rev (1m)0.81%
EPS NY rev (3m)2.79%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)1400.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.52
P/tB 2.52
EV/EBITDA N/A
EPS(TTM)-2.91
EYN/A
EPS(NY)-2.98
Fwd EYN/A
FCF(TTM)-2.51
FCFYN/A
OCF(TTM)-2.38
OCFYN/A
SpS0
BVpS7
TBVpS7
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -41.07%
ROE -46.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.89%
ROA(5y)-16.39%
ROE(3y)-26.58%
ROE(5y)-20.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 152.73%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.27
Quick Ratio 10.27
Altman-Z 8.57
F-Score1
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)141.82%
Cap/Depr(5y)112.16%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.46%
EPS Next Y-12.62%
EPS Next 2Y-5.62%
EPS Next 3Y-0.54%
EPS Next 5Y11.63%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-87.68%
Revenue Next 2Y124.04%
Revenue Next 3Y166.11%
Revenue Next 5Y133.17%
EBIT growth 1Y-7.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.91%
EBIT Next 3Y2.29%
EBIT Next 5Y17.62%
FCF growth 1Y-14.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.93%
OCF growth 3YN/A
OCF growth 5YN/A

DENALI THERAPEUTICS INC / DNLI FAQ

What is the ChartMill fundamental rating of DENALI THERAPEUTICS INC (DNLI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to DNLI.


Can you provide the valuation status for DENALI THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to DENALI THERAPEUTICS INC (DNLI). This can be considered as Overvalued.


How profitable is DENALI THERAPEUTICS INC (DNLI) stock?

DENALI THERAPEUTICS INC (DNLI) has a profitability rating of 1 / 10.


How financially healthy is DENALI THERAPEUTICS INC?

The financial health rating of DENALI THERAPEUTICS INC (DNLI) is 5 / 10.